CAT # Product Name Description
CPD1802 CPD1802
CPD0261 CPD0261
CPD1815 BI-3812 BI-3812 is a potent inhibitor of the interaction of the BTB/POZ domain of BCL6 with several co-repressors. It acts by inhibiting the BCL6::Co-repressor complex formation.
CPD2801-A8 CPD2801-A8
CPD2801-A6 CPD2801-A6
CPD2801-A4 CPD2801-A4
CPD1588-B3 CPD1588-B3
CPD1815-A4 CPD1815-A4
CPD1815-A10 CPD1815-A10
CPD1815-A7 CPD1815-A7
CPD2500-A8 CPD2500-A8
CPD2500-A4 CPD2500-A4
CPD2500-A3 CPD2500-A3
CPD2500-A6 CPD2500-A6
CPD2802-A2 CPD2802-A2
CPD2802-A3 CPD2802-A3
CPD2802-A1 CPD2802-A1
CPD2802-SM1 CPD2802-SM1
CPD1110-A4 CPD1110-A4
CPD1110-A2 CPD1110-A2 1202402-45-6 R-isomer
CPD1110-A1 CPD1110-A1
CPD1639-A7 CPD1639-A7
CPD1639-A6 CPD1639-A6

Contact Us


Latest News

  • Top 7 Trends In Pharmaceutical Research In 2018

    Top 7 Trends In Pharmaceutical Research I...

      Being under ever-increasing pressure to compete in a challenging economic and technological environment, pharmaceutical and biotech companies must continually innovate in their R&D programmes to stay ahead ...

  • ARS-1620: A promising new inhibitor for KRAS-mutant cancers

    ARS-1620: A promising new inhibitor for K...

    According to a study published in Cell, researchers have developed a specific inhibitor for KRASG12C called ARS-1602 that induced tumor regression in mice. “This study provides in vivo evidence that mutant KRAS can be...

  • AstraZeneca receives regulatory boost for oncology drugs

    AstraZeneca receives regulatory boost for...

    AstraZeneca received a double boost for its oncology portfolio on Tuesday, after US and European regulators accepted regulatory submissions for its drugs, the first step towards winning approval for these medicines. ...

WhatsApp Online Chat !